Medlab Clinical Ltd (ASX:MDC), an Australian biotech using delivery platforms to enhance medicines is pleased to announce the execution of a Master Services Agreement with WEP Clinical Ltd for the exclusive development and delivery of Named Patient Programmes
AusCann Group Holdings Ltd (ASX:AC8), an Australian based pharmaceutical company focused on the development, production and distribution of cannabinoid-based medicines within Australia and internationally, is pleased to announce that it has entered into a scheme implementation deed (SID) with CannPal Animal Therapeutics Limited.
Cann Global continued to drive sales throughout the quarter resulting in cash receipts from customers of $333k up 54.6% on the prior corresponding period, but lower than the prior quarter due to shipping delays and therefore delayed payment on contracted sales.
Cann Global Limited (ASX:CGB) is pleased to confirm that the 1 for 4 renounceable entitlement offer announced on 3 July 2020 (Entitlement Offer), closed on Thursday 23 July 2020.
Cann Global Ltd (ASX:CGB) today confirms that its Directors and largest shareholders intend to participate in the rights issues announced on 3 July 2020.
Cann Global Limited's (ASX:CGB) medical Cannabis research division, Medical Cannabis Research Group Pty Ltd (MCRG) entered into a research agreement to research the possibility of the use of cannabis in the treatment of autoimmune disease, specifically multiple sclerosis (MS).
The Board of Cann Global Limited (ASX:CGB) wishes to update our shareholders on the operations of its 55% owned subsidiary Cann Global Asia Pty Ltd, and its activities in Laos PDR.
